Here are the ones that fit the bill so far: Semaglutide: For weight loss, 2.4 mg of semaglutide (compared with 1 mg for diabetes management) is typically administered once weekly
The common hepatic branch of the vagus is not required to mediate the glycemic and food intake suppressive effects of glucagon-like-peptide-1
Vision changes: More likely to occur if you have diabetic retinopathy
Choosing dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter-2 inhibitors, or both, as add-ons to metformin: patient baseline characteristics are crucial
GLP-1 agonists lower blood sugar levels and improve glycemic control in people with type 2 diabetes, often delaying the need to start insulin
Robert Kushner: Yeah, compounding is something that the FDA approves when a medication needs to be modified for a particular individual